<![CDATA[Rezatapopt Generates Rapid, Durable Responses Across Subgroups in Pretreated TP53 Y220C-Mutated Ovarian Cancer]]...
Rezatapopt (PC14586), an investigational first-in-class, selective p53 reactivator, demonstrated clinically meaningful activity and a manageable safety profile in heavily pretreated patients with advanced ovarian cancer harboring a TP53 Y220C mutation …